|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:approvedBy
|
gptkb:FDA
alendronate in 1995 (US)
|
|
gptkbp:category
|
antiresorptive agent
|
|
gptkbp:contraindication
|
renal impairment
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:effect
|
increase bone mineral density
reduce fracture risk
|
|
gptkbp:example
|
gptkb:ibandronate
gptkb:risedronate
gptkb:alendronate
gptkb:zoledronic_acid
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:halfLife
|
long (years in bone)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bisphosphonates
|
|
gptkbp:mechanismOfAction
|
inhibit osteoclast-mediated bone resorption
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:notRecommendedFor
|
children
pregnant women
|
|
gptkbp:prescribes
|
gptkb:physician
|
|
gptkbp:sideEffect
|
hypocalcemia
Esophageal cancer
osteonecrosis of the jaw
atypical femoral fractures
|
|
gptkbp:structure
|
contain two phosphonate groups
|
|
gptkbp:usedFor
|
gptkb:bone
gptkb:Paget's_disease_of_bone
bone metastases
hypercalcemia of malignancy
|
|
gptkbp:bfsParent
|
gptkb:hypercalcemia
|
|
gptkbp:bfsLayer
|
5
|